Accumulating evidence has shown that PERK inhibition effectively decreases tumor growth, metastasis, and chemoresistance, demonstrating PERK as a potential molecular target in anticancer therapeutic strategies [14]. The gene discussed is EIF2AK3; the disease is neoplasm.